CAR T Cell Therapy May Change Cancer Patients’ Own Weak T Cells into “Bionic Killing Machines”
Aurora Biopharma is a Cambridge, MA-based, clinical-stage company that is developing state-of-the-art cancer immunotherapy, utilizing a form of adoptive cell transfer called Chimeric Antigen Receptor (CAR) T Cell Therapy. The therapy genetically edits patients’ T cells to express a CAR specific to the type of cancer present, which enables targeted killing of cancer cells. The U.S. Food & Drug Administration has awarded Aurora Biopharma’s CAR T Cell Therapy with its Breakthrough Therapy Designation for the therapy’s treatment of pediatric and adult acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Aurora Biopharma’s CAR T Cell Therapy can change a cancer patient’s own weak T cells into “bionic” killing machines—highly targeted armies that can kill cancer. The patient’s T cells are removed from a blood draw, genetically engineered in a laboratory, expanded to almost a billion CAR T cells, and re-infused back into the patient, where they are exponentially better able to kill cancer.
Aurora’s CAR T Cell therapies have been shown to kill multiple types of solid tumors, in both pre-clinical animal studies and completed human trials. In two completed Phase I/II clinical trials in Sarcoma and Glioblastoma, Aurora’s revolutionary CAR T Cell therapies AU101 and AU105 showed that the therapy can be safe, catalyze tumor killing, and increase survival rates.
Founded in 2012, Aurora Biopharma has received grants and raised funding in the form of convertible debt. Aurora is backed by the Live Like Bella Foundation, which focuses on pediatric cancer.
In upcoming news, Aurora Biopharma is presenting at the NYC Oncology Investor Conference, occurring on May 8-9 at the office of Wilson Sonsini in New York City. Learn more and register to attend the conference at www.nyconcologyconference.com.